



ORIGINAL ARTICLE

## Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: a triple-masked controlled trial<sup>☆</sup>

Roya Kelishadi<sup>a,\*</sup>, Shadi Salek<sup>a</sup>, Mehdi Salek<sup>a</sup>,  
Mahin Hashemipour<sup>a</sup>, Mahsa Movahedian<sup>b</sup>

<sup>a</sup> Pediatrics Department, Child Growth and Development Research Center and Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>b</sup> Department of English Linguistics, University of Isfahan, Isfahan, Iran

Received 19 March 2013; accepted 19 June 2013

Available online 16 October 2013

### KEYWORDS

Vitamin D;  
Metabolic syndrome;  
Insulin resistance;  
Children and  
adolescents

### Abstract

**Objective:** this triple-masked controlled trial aimed to assess the effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in obese children and adolescents.

**Methods:** the study comprised 50 participants, aged 10 to 16 years, who were randomly assigned into two groups of equal number. In this 12-week trial, one group received oral vitamin D (300,000 IU) and the other group received placebo. Cardiometabolic risk factors, insulin resistance, and a continuous value of metabolic syndrome (cMetS) were determined. Statistical analysis was conducted after adjustment for covariate interactions.

**Results:** overall, 21 patients in the vitamin D group and 22 in the placebo group completed the trial. No significant difference was observed in the baseline characteristics of the two groups. After the trial, in the vitamin D group, serum insulin and triglyceride concentrations, as well as HOM-IR and C-MetS decreased significantly, both when compared with the baseline and with the placebo group. No significant difference was observed when comparing total cholesterol, LDL-C, HDL-C, fasting blood glucose, and blood pressure.

**Conclusion:** the present findings support the favorable effects of vitamin D supplementation on reducing insulin resistance and cardiometabolic risk factors in obese children.

© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](http://creativecommons.org/licenses/by-nc-nd/4.0/)

<sup>☆</sup> Please cite this article as: Kelishadi R, Salek S, Salek M, Hashemipour M, Movahedian M. Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: a triple-masked controlled trial. J Pediatr (Rio J). 2014;90:28–34.

\* Corresponding author.

E-mail: [kelishadi@med.mui.ac.ir](mailto:kelishadi@med.mui.ac.ir) (R. Kelishadi).

**PALAVRAS-CHAVE**

Vitamina D;  
Síndrome metabólica;  
Resistência à insulina;  
Crianças e  
adolescentes

**Efeitos da suplementação de vitamina D sobre a resistência à insulina e fatores de risco cardiometabólico em crianças com síndrome metabólica: ensaio clínico triplo-cego controlado****Resumo**

**Objetivo:** este ensaio clínico triplo-cego controlado visa investigar os efeitos da suplementação de vitamina D sobre a resistência à insulina e os fatores de risco cardiometabólico em crianças e adolescentes obesos.

**Métodos:** o estudo contou com 50 participantes com idade entre 10 e 16 anos, aleatoriamente divididos em dois grupos de igual número de participantes. Neste ensaio clínico de 12 semanas, um grupo recebeu vitamina D via oral (300000 IU) e o outro grupo recebeu placebo. Foram determinados fatores de risco cardiometabólico, resistência à insulina e valor contínuo da síndrome metabólica (cMetS). A análise estatística foi conduzida após o ajuste das interações covariáveis.

**Resultados:** no todo, 21 pacientes no grupo vitamina D e 22 no grupo placebo concluíram o ensaio clínico. Nenhuma diferença significativa foi encontrada nas características de base dos dois grupos estudados. Após o ensaio clínico, no grupo vitamina D, as concentrações séricas de insulina e triglicerídeos, bem como HOMA-RI e cMetS caíram significativamente em comparação ao início do estudo; e também em comparação ao grupo placebo. Nenhuma diferença significativa foi vista ao comparar o colesterol total, LDL-C, HDL-C, glicemia de jejum e pressão sanguínea.

**Conclusão:** nossas conclusões indicam efeitos favoráveis da suplementação de vitamina D sobre a redução da resistência à insulina e de fatores de risco cardiometabólico em crianças obesas.

© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](#)

**Introduction**

Most chronic non-communicable diseases and their risk factors begin early in life. Therefore, in recent years, much attention has been focused on the primary prevention of diseases from childhood. The long-term effects of childhood obesity, such as cardiometabolic risk factors including metabolic syndrome (MetS) are of special concern.<sup>1</sup>

In this context, prevention and early control of risk factors are of crucial importance. MetS is an underlying cause of most chronic diseases, and insulin resistance is suggested to have an underlying role in the development of MetS. Such disorders are not limited to adults and to industrialized countries, rather, they are becoming as an important health problem for children and adolescents in several countries.<sup>2</sup> The authors' previous national studies reported a high prevalence of MetS and cardiometabolic risk factors in Iranian children and adolescents.<sup>3,4</sup> In recent years, significant relationships have been documented between vitamin D deficiency and various non-communicable diseases, notably cardiovascular diseases and diabetes, as well as with their predisposing factors, such as MetS and insulin resistance. Vitamin D has an important role in glucose and insulin metabolism.<sup>5</sup> It affects pancreatic islet cells through its receptors and may increase insulin secretion. Vitamin D deficiency leads to elevated PTH levels, and in turn to decreased insulin sensitivity. Moreover, vitamin D has anti-inflammatory and immune modulating effects, and might lead to a decrease in insulin resistance and an increase in insulin secretion by modulating the immune system.<sup>6</sup> Low serum levels of vitamin D are suggested to be associated with insulin resistance and cardiometabolic risk factors even in young age. Thus, different doses of vitamin

D supplementation are proposed for prevention of these risk factors in healthy children and adolescents.<sup>7</sup> However, whether vitamin D supplementation would improve insulin sensitivity and metabolic risk factors in the pediatric age group is controversial. The current study aimed to investigate the effects of oral vitamin D supplementation on insulin resistance and cardiometabolic risk factors in obese children and adolescents.

**Methods**

This triple-masked controlled trial was conducted in 2012 in Isfahan, Iran, and was approved by the Research Council and the Ethics Committee of the Isfahan University of Medical Sciences. The trial was registered with the code IRCT201110271434N5 in the Iranian Registry of Clinical Trials, which is a primary registry in the World Health Organization (WHO) Registry Network. This trial was conducted in accordance with the principles of the Helsinki Declaration. An informed consent was obtained from parents and oral assent from participants. Considering an  $\alpha$  error of 0.05 and a  $\beta$  error of 20%, and also considering the effect of vitamin D supplementation on insulin sensitivity in a previous trial among obese individuals,<sup>8</sup> the sample size was calculated as 20 in the intervention group, and 20 in the placebo group. Due to possible attrition during the trial, the sample size was increased to 25 in each group.

**Participants**

The study was conducted among children and adolescents referred to the pediatrics clinics affiliated to Isfahan

University of Medical Sciences. Eligibility criteria were age between 10 years and 16 years, body mass index equal to or greater than three Z-scores,<sup>9</sup> and presence of MetS.<sup>10,11</sup> Exclusion criteria were any medication or supplementation use and any chronic disease. Obese children and adolescents were invited to participate, and if after receiving their laboratory data, they fulfilled the criteria of MetS, they were recruited to the trial. Sampling continued until reaching the necessary number of participants for the trial. The demographic variables were determined through a validated questionnaire.<sup>12</sup>

### Physical examination and laboratory tests

Anthropometric indexes, as well as systolic (SBP) and diastolic (DBP) blood pressure were measured by trained nurses according to standard protocols, using calibrated instruments. Fasting venous blood sample was examined for fasting plasma glucose (FPG) and lipid profile by autoanalyzer with standard kits (Pars Azmoun - Tehran, Iran). Serum concentration of 25-hydroxy vitamin D (25(OH)D) was analyzed using the chemiluminescent immunoassay (CLIA) method (25 OH VitD CLIA kit, Diasorin - Stillwater, MN, United States); the kit's expected range is 4 to 150 ng/mL. The lowest reportable value was 4.0 ng/mL, which is based on an inter-assay precision that approximates 20% CV (functional sensitivity).

Plasma insulin was measured by radioimmunoassay (RIA) (LINCO Research Inc), which is 100% specific for human insulin with less than 0.2% cross-reactivity with human proinsulin and no cross reactivity with c-peptide or insulin-like growth factor. Insulin resistance (IR) was calculated on the basis of the homeostasis model assessment of IR (HOMA-IR), using the following formula:

$$[\text{HOMA-IR} = (\text{fasting insulin (mU/L)} \times \text{fasting glucose (mmol/L)}) / 22.5].$$

### Definition of cardiometabolic risk factors and MetS

Cardiometabolic risk factors were defined according to the latest cut-off points provided by the National Heart, Lung, and Blood Institute for the pediatric age group.<sup>13</sup> As there is no universal definition of MetS in the pediatric age group, a continuous value of MetS (cMetS) was used, as recommended by the American Diabetes Association and the European Association for the Study of Diabetes for children and adolescents.<sup>9</sup> The cMetS score was derived by first standardizing the residuals for waist circumference (WC), high density lipoprotein-cholesterol (HDL-C), triglycerides (TG), fasting blood glucose (FBG), and mean arterial blood pressure (MAP) by regressing them based on age and gender to account for age- and gender-related differences. MAP was calculated using the following equation:  $\text{MAP} = [(\text{SBP} - \text{DBP}) / 3] + \text{DBP}$ . Since the standardized HDL-C is inversely related to the MetS risk, it was multiplied by -1. The cMetS score was calculated as the sum of the standardized residuals (Z-scores) for the individual variables. A higher cMetS score indicates a less favorable metabolic profile. The cMetS score has been previously validated by the authors in Iranian children and adolescents.<sup>11</sup>

### Medication and placebo

The Zahravi Pharmaceutical company, which manufactures soft gel capsules containing 50,000 IU of vitamin D<sub>3</sub>, collaborated with the trial in preparing placebo. They were identical in appearance with the vitamin D capsules, and both were tasteless and odorless.

### Study intervention

The trial statistician generated a randomization list using Stata, version 9 (College Station - TX, United States). Participants were randomly assigned to two groups of equal number. All trial staff, participants, and the statistician were masked to treatment allocation throughout the study.

One group received 300,000 IU (one capsule per week) of vitamin D<sub>3</sub>,<sup>14</sup> and the other group received placebo. Both groups received similar recommendations for healthy eating and reduction of sedentary activities.

Compliance with consumption of medication or placebo was assessed by weekly phone follow-up and monthly visits in the clinic. Twelve weeks after randomization, all baseline clinical and laboratory examinations were repeated in both groups. The entire program was offered free of charge.

### Statistical analysis

Data analyses were performed using the Statistical Package for Social Sciences (SPSS), version 20.0 (SPSS Inc. - Chicago, IL, United States). The normality of the distribution of variables was confirmed by the Kolmogorov-Smirnov test. The intention to treat principle was used throughout the analysis. Student's *t*-test was used to compare the mean of quantitative variables before and after the intervention. The comparison of pre-and-post-intervention within each group was calculated by paired *t*-test. Analysis of covariance were used to adjust results for the dependent variables measured before and after the trial for treatment covariate interactions. All values were reported as mean  $\pm$  SD.  $P_{\text{time}}$ ,  $P_{\text{group}}$  and  $P_{\text{time} \times \text{group}}$  were calculated for all variables.

### Results

The study flow chart shows the screening, randomization, and follow-up of the participants (Fig. 1). Overall, 21 patients in the vitamin D group and 22 in the placebo group completed the trial. No significant difference was observed in the baseline characteristics of the two groups studied. The intra-group and inter-group differences in variables before and after the trial are presented in Table 1.

At baseline, the mean concentrations of serum 25(OH)D were not significantly different between the groups studied; after the trial, the group receiving vitamin D had significant intra-group ( $p=0.01$ ) and inter-group ( $p=0.02$ ) increases. This was confirmatory evidence of the compliance of participants in taking vitamin D capsules.

After the trial, in the vitamin D group, serum TG concentration decreased significantly compared with the baseline ( $p=0.04$ ); and also compared with the placebo group ( $p=0.02$ ). A significant decrease was observed in

**Table 1** Characteristics of participants at baseline and after the trial.

Variables	Vitamin D Group <sup>a</sup> (n=21)	Placebo Group <sup>b</sup> (n=22)	p overall <sup>c</sup>	P <sub>time</sub> <sup>d</sup>	P <sub>group</sub> <sup>e</sup>	P <sub>time × group</sub> <sup>f</sup>	P <sub>time × age</sub> <sup>g</sup>
<i>BMI (kg/m<sup>2</sup>)</i>							
Before	28.08 ± 1.06	27.81 ± 1.04	0.61	0.42	0.56	0.41	0.55
After	27.91 ± 1.04	27.24 ± 1.01	0.68				
p <sup>h</sup>	0.51	0.48	-				
<i>WC (cm)</i>							
Before	90.08 ± 6.01	90.03 ± 5.04	0.64	0.52	0.46	0.61	0.45
After	89.02 ± 5.04	89.07 ± 5.01	0.58				
p <sup>h</sup>	0.61		0.58	-			
<i>WhtR</i>							
Before	06/01 ± 0/02	06.03 ± 0.04	0.61	0.47	0.51	0.64	0.51
After	06.01 ± 0.01	06.02 ± 0.05					
p <sup>h</sup>	0.51	0.48	-				
<i>25(OH)D (ng/mL)</i>							
Before	18.27 ± 2.04	17.91 ± 2.27	0.48	0.06	0.04	0.02	0.03
After	32.01 ± 2.14	19.07 ± 2.01	0.02				
p <sup>h</sup>	0.01	0.15	-				
<i>Insulin(μU/L)</i>							
Before	14.27 ± 1.32	14.19 ± 1.20	0.31	0.37	0.31	0.51	0.27
After	13.71 ± 1.58	14.07 ± 1.04	0.02				
p <sup>h</sup>	0.04	0.28	-				
<i>FBG (mg/dL)</i>							
Before	94.27 ± 5.32	92.20 ± 6.21	0.48	0.61	0.41	0.52	0.47
After	90.71 ± 4.58	90.07 ± 5.64	0.21				
p <sup>h</sup>	0.06	0.28	-				
<i>HOMA-IR</i>							
Before	3.21 ± 0.11	3.15 ± 0.26	0.48	0.42	0.51	0.32	0.25
After	2.81 ± 0.25	3.07 ± 0.14	0.02				
p <sup>h</sup>	0.04	0.28	-				
<i>TG(mg/dL)</i>							
Before	141.21 ± 24.15	143.15 ± 23.26	0.48	0.41	0.31	0.35	0.27
After	102.81 ± 27.20	137.07 ± 25.14	0.02				
p <sup>h</sup>	0.04	0.08	-				
<i>TC(mg/dL)</i>							
Before	161.50 ± 3.21	164.18 ± 5.18	0.27	0.32	0.25	0.21	0.51
After	160.18 ± 2.35	162.15 ± 4.21	0.35				
p <sup>h</sup>	0.54	0.41	-				
<i>HDL-C(mg/dL)</i>							
Before	47.06 ± 4.01	48.72 ± 4.12	0.34	0.12	0.26	0.38	0.51
After	45.21 ± 3.18	44.35 ± 2.19	0.48				
p <sup>h</sup>	0.45	0.46	-				
<i>LDL-C(mg/dL)</i>							
Before	97.01 ± 4.19	95.68 ± 2.87	0.58	0.76	0.861	0.57	0.51
After	93.17 ± 5.21	92.56 ± 4.12	0.67				
p <sup>h</sup>	0.08	0.07	-				
<i>MAP (mmHg)</i>							
Before	134.01 ± 5.89	136.61 ± 6.08	0.53	0.76	0.81	0.58	0.52
After	131.47 ± 4.69	135.26 ± 4.52	0.07				
p <sup>h</sup>	0.06	0.12	-				

Table 1 (Continued)

Variables	Vitamin D Group <sup>a</sup> (n=21)	Placebo Group <sup>b</sup> (n=22)	p overall <sup>c</sup>	Ptime <sup>d</sup>	Pgroup <sup>e</sup>	P time × group <sup>f</sup>	Ptime × age <sup>g</sup>
<i>C-MetS</i>							
Before	4.21 ± 0.89	4.36 ± 0.78	0.51	0.26	0.41	0.38	0.42
After	3.17 ± 0.61	4.01 ± 0.52	0.02				
p <sup>h</sup>	0.04	0.12	-				

BMI, body mass index; C-MetS, continuous metabolic syndrome; FBG, fasting blood glucose; HDL-C, high density lipoprotein-cholesterol; HOMA-IR, homeostasis model of assessment - insulin resistance; LDL-C, low density lipoprotein-cholesterol; MAP, mean arterial blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHtR, waist to height ratio; 25(OH)D, 25-hydroxyvitamin D. All values are presented as mean ± SD.

<sup>a</sup> 300,000 IU vitamin D<sub>3</sub>.

<sup>b</sup> Softgel capsules identical to the vitamin D<sub>3</sub> capsules.

<sup>c</sup> p-values present comparison of baseline and end point values between two groups (computed by Student's *t*-test for independent samples).

<sup>d</sup> p-values demonstrate the effect of time (computed by analysis of the covariance).

<sup>e</sup> p-values represent the effect of grouping (computed by analysis of the covariance).

<sup>f</sup> p-values represent the time\*group interaction (computed by analysis of the covariance).

<sup>g</sup> p-values represent the time\*age interaction (computed by analysis of the covariance).

<sup>h</sup> p-values present comparison of baseline and end point values within each group (computed by Student's *t*-test for paired samples).




Figure 1 Study algorithm.

serum insulin levels and HOMA-IR in the vitamin D group at the end of the study in comparison with the baseline ( $p=0.04$ ). At the end of the study, the serum insulin levels and HOMA-IR had a significant difference between the groups ( $p=0.02$  and  $p=0.02$ , respectively), showing improvement in IR in the group receiving vitamin D. Comparison of cMetS at the baseline and after the trial showed significant decrease in the vitamin D group when compared to the placebo group ( $p=0.04$ ). However, no significant differences were observed when comparing the serum levels of total cholesterol, LDL-C, HDL-C, FBG, and BP at baseline and after the trial both intra-group ( $p=0.54$ ,  $p=0.08$ ,  $p=0.45$ ,  $p=0.06$ , and  $p=0.06$ , respectively) and inter-group ( $p=0.41$ ,  $p=0.07$ ,  $p=0.46$ ,  $p=0.28$ , and  $p=0.07$ ).

## Discussion

To the best of the authors' knowledge, the present study is one of the first of its kind in the pediatric age group, and revealed favorable effects of oral vitamin D<sub>3</sub> (300,000

IU) on insulin resistance, MetS, and TG in obese children and adolescents. There is increasing evidence that vitamin D deficiency is associated with risk factors of non-communicable diseases, including components of the MetS and other cardiometabolic risk factors even in children and adolescents.<sup>15-17</sup> Insulin resistance is considered as one of the main underlying causes of MetS. Some studies have demonstrated an inverse relationship between vitamin D levels and insulin resistance.<sup>18,19</sup> Inflammatory cytokine production is considered to be one of the mechanisms of the effect of vitamin D on insulin resistance; inflammatory cytokines are associated with both obesity and insulin resistance.<sup>20</sup> There is further evidence of a relationship between vitamin D metabolism and diabetes mellitus. Vitamin D is involved in insulin secretion and probably on its function, hypophysis regulation and glucose homeostasis, which eventually can lead to the development of MetS.<sup>21</sup> It has been suggested that low serum levels of vitamin D may increase insulin resistance, and in turn the risk of diabetes mellitus type 2 over time.<sup>20</sup>

Previous trials on the effects of vitamin D on cardiometabolic risk factors and insulin resistance have been performed with adults.<sup>19,22-26</sup>

The present results confirm a significant relationship between vitamin D deficiency and increased blood pressure, TG, insulin resistance, and MetS. The findings of this study are in agreement with those of other clinical trials conducted among adults; and an inverse relationship has been observed between serum concentration of vitamin D and the risk of MetS and insulin resistance.<sup>22-24</sup> Furthermore, several cross-sectional studies presented the same results.<sup>19,25,26</sup> For instance, in a study among postmenopausal women, an inverse relationship was documented between serum levels of vitamin D with TG, HDL/TG, and MetS, but the corresponding figures were not significant for LDL-C, HDL-C, and insulin.<sup>22</sup>

Conversely, other studies conducted among adults did not document a significant association between vitamin D levels and the abovementioned indexes.<sup>27,28</sup> Likewise, a cross-sectional study on Turkish high school students did not

find a significant correlation between vitamin D levels and insulin resistance or MetS.<sup>29</sup> Differences in the age groups studied, severity of weight excess, and cardiometabolic risk factors, as well as the doses of vitamin D supplementation can explain the controversies in the findings of various studies. The dose and interval of vitamin D supplementation for improving the serum vitamin D levels of children remain undetermined.<sup>30</sup>

### Study limitations and strengths

Although some significant differences were observed, which indicate that a sufficient number of subjects were studied, a larger sample size with longer period of follow-up perhaps would have obtained more favorable results. The strengths of the present study are its novelty in the pediatric age group and the assessment of independent association of vitamin D with the risk factors studied.

### Conclusion

Vitamin D supplementation was inversely associated with insulin resistance and some cardiometabolic risk factors. Vitamin D supplementation may have beneficial effects on controlling some complications of childhood obesity.

### Funding

This trial was conducted as a thesis funded by the Isfahan University of Medical Sciences.

### Conflicts of interest

The authors declare no conflicts of interest.

### Acknowledgments

This study was conducted as a thesis funded by Isfahan University of Medical Sciences. The authors would like to thank the participants of the study and their families.

### References

1. da Conceição-Machado ME, Silva LR, Santana ML, Pinto EJ, Silva Rde C, Moraes LT, et al. Hypertriglyceridemic waist phenotype: association with metabolic abnormalities in adolescents. *J Pediatr (Rio J)*. 2013;89:56–63.
2. Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. *Epidemiol Rev*. 2007;29:62–76.
3. Kelishadi R, Ardalan G, Gheiratmand R, Adeli K, Delavari A, Majdzadeh R, et al. Paediatric metabolic syndrome and associated anthropometric indices: the CASPIAN Study. *Acta Paediatr*. 2006;95:1625–34.
4. Khashayar P, Heshmat R, Qorbani M, Motlagh ME, Aminae T, Ardalan G, et al. Metabolic syndrome and cardiovascular risk factors in a national sample of adolescent population in the middle east and north africa: the CASPIAN III Study. *Int J Endocrinol*. 2013;2013:702095.
5. Patel A, Zhan Y. Vitamin D in cardiovascular disease. *Int J Prev Med*. 2012;3:664.
6. Boucher BJ. Vitamin D insufficiency and diabetes risks. *Curr Drug Targets*. 2011;12:61–87.
7. Salo A, Logomarsino JV. Relationship of vitamin D status and cardiometabolic risk factors in children and adolescents. *Pediatr Endocrinol Rev*. 2011;9:456–62.
8. Harris SS, Pittas AG, Palermo NJ. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. *Diabetes Obes Metab*. 2012;14:789–94.
9. Borghi E, de Onis M, Garza C, Van den Broeck J, Frongillo EA, Grummer-Strawn L, et al. Construction of the World Health Organization child growth standards: selection of methods for attained growth curves. *Stat Med*. 2006;25:247–65.
10. Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2005;28:2289–304.
11. Shafiee G, Kelishadi R, Heshmat R, Qorbani M, Motlagh ME, Aminae T, et al. First report on validity of a continuous metabolic syndrome score as an indicator for metabolic syndrome in a national sample of pediatric population: the CASPIAN-III Study. *Endocrinol Polska*. 2013 (in press).
12. Kelishadi R, Mirghaffari N, Poursafa P, Gidding SS. Lifestyle and environmental factors associated with inflammation, oxidative stress and insulin resistance in children. *Atherosclerosis*. 2009;203:311–9.
13. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128:S213–56.
14. Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007;357:266–81.
15. Nam GE, Kim DH, Cho KH, Park YG, Han KD, Kim SM, et al. 25-Hydroxyvitamin D insufficiency is associated with cardiometabolic risk in Korean adolescents: the 2008-2009 Korea National Health and Nutrition Examination Survey (KNHANES). *Public Health Nutr*. 2012;1–9.
16. Pacifico L, Anania C, Osborn JF, Ferraro F, Bonci E, Olivero E, et al. Low 25(OH)D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian children and adolescents. *Eur J Endocrinol*. 2011;165:603–11.
17. Ganji V, Zhang X, Shaikh N, Tangpricha V. Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001-2006. *Am J Clin Nutr*. 2011;94:225–33.
18. Petchey WG, Hickman IJ, Duncan E, Prins JB, Hawley CM, Johnson DW, et al. The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial. *BMC Nephrol*. 2009;10:41.
19. Park HY, Lim YH, Kim JH, Bae S, Oh SY, Hong YC. Association of serum 25-hydroxyvitamin D levels with markers for metabolic syndrome in the elderly: a repeated measure analysis. *J Korean Med Sci*. 2012;27:653–60.
20. Muldowney S, Lucey AJ, Paschos G, Martinez JA, Bandarra N, Thorsdottir I, et al. Relationships between vitamin D status and cardio-metabolic risk factors in young European adults. *Ann Nutr Metab*. 2011;58:85–93.
21. Delvin EE. Importance of vitamin D in insulin resistance. *Bull Acad Natl Med*. 2011;195:1091–103.
22. Chacko SA, Song Y, Manson JE, Van Horn L, Eaton C, Martin LW, et al. Serum 25-hydroxyvitamin D concentrations in relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women. *Am J Clin Nutr*. 2011;94:209–17.

23. Salekzamani S, Neyestani TR, Alavi-Majd H, Houshiarrad A, Kalayi A, Shariatzadeh N, et al. Is vitamin D status a determining factor for metabolic syndrome? A case-control study. *Diabetes Metab Syndr Obes.* 2011;4:205–12.
24. Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. *Metabolism.* 2012;61:661–6.
25. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. *Diabetes Care.* 2005;28:1228–30.
26. Brenner DR, Arora P, Garcia-Bailo B, Wolever TM, Morrison H, El-Sohemy A, et al. Plasma vitamin D levels and risk of metabolic syndrome in Canadians. *Clin Invest Med.* 2011;34:E377.
27. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. *Diabetologia.* 2010;53:2112–9.
28. Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, Hasanzadeh J. Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients. *Asia Pac J Clin Nutr.* 2011;20:521–6.
29. Erdönmez D, Hatun S, Çizmeciöğlü FM, Keser A. No relationship between vitamin D status and insulin resistance in a group of high school students. *J Clin Res Pediatr Endocrinol.* 2011;3:198–201.
30. Cavalier E, Faché W, Souberbielle JC. A randomised, double-blinded, placebo-controlled, parallel study of vitamin D3 supplementation with different schemes based on multiples of 25,000IU doses. *Int J Endocrinol.* 2013;2013:327265.